Whitfield B. Growdon, MD

Articles by Whitfield B. Growdon, MD

Dr Growdon on the Withdrawal of Later-Line Indication For Olaparib in BRCA-Mutated Ovarian Cancer

July 28th 2023

Whitfield B. Growdon, MD, expands on the FDA’s decision to withdraw the later-line indication of olaparib for patients with BRCA-mutated ovarian cancer.

Latest Updated Articles

Trending on OncLive

FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC

PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings

Olverembatinib Plus Blinatumomab Yields High Early-Phase CR/CRi Rates in R/R Ph+ CML and B-ALL

Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL

Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL